NEW YORK (GenomeWeb) – Signal Genetics announced today the closing of the public offering of its common shares, raising $9 million in gross proceeds. 

The Carlsbad, Calif.-based molecular diagnostics firm offered 3,214,285 shares of its stock at $2.80 per share and has granted the offering's underwriters a 45-day overallotment option to purchase up to 482,142 shares of its common stock. Aegis Capital and Chardan Capital Markets are the joint book-running managers on the offering.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.